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Human immunodeficiency virus type (HIV)-1 circulating
recombinant form 08_BC (CRF08_BC), carrying recombi-
nant reverse transcriptase (RT) gene from subtype B and
C, has recently become highly prevalent in Southern
China. As the number of patients infected by CRF08_BC
increases, it is important to characterize the drug resis-
tance mutations of CRF08_BC, especially against widely
used antiretrovirals. In this study, clinically isolated virus
was propagated in human peripheral blood mononuclear
cells (PBMCs) with increasing concentrations of nevira-
pine (NVP), efavirenz (EFV) or lamivudine (3TC). Three
different resistance patterns led by initial mutations of
Y181C, E138G and Y188C were detected after in vitro
selection with NVP. Virus variants with initial mutations,
in combination with three other previously reported sub-
stitutions (K20R, D67N, V90I, K101R/E, V106I/A, V108I,
F116L, E138R, A139V, V189I, G190A, D218E, E203K,
H221Y, F227L, N348I and T369I) or novel mutations
(V8I, S134N, C162Y, L228I, Y232H, E396G and D404N)
developed during NVP selection. EFV-associated varia-
tions contained two initial mutations (L100I and Y188C)
and three other mutations (V106L, F116Y and T139V).
Phenotypic analyses showed that E138R, Y181C and
G190A contributed high level resistance to NVP, while
L100I and V106L significantly reduce virus susceptibility
to EFV. Y188C resulted in a 20-fold reduction of suscept-
ibility to both NVP and EFV. M184V was selected by 3TC
as expected. This mutation, alone or with V90I or D67N,
decreased 3TC susceptibility by over 1000 folds. These
results have brought new insight into the development of
drug-related mutations in patients and provided useful
information for the optimization of antiretroviral
regimens.
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